Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05330858 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
A Phase 1 study of Pharmacokinetics, sponsored by Alumis.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT05330858 is a Phase 1 study of Pharmacokinetics that has completed, run by Alumis. The registered enrollment target is 14 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05330858, a Phase 1 study of Pharmacokinetics, has completed, sponsored by Alumis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
Conditions Studied
Interventions
- DRUG ESK-001
- DRUG Rabeprazole
Study Locations (1)
California
- Alumis Central Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05330858
The ClinicalTrials.gov registry entry for NCT05330858 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (77% lower). The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which ESK-001 is the first listed.
NCT05330858 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05330858 about?
NCT05330858 is a clinical study titled "Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants". This is a single-center, in-house, open-label, crossover study in 15 healthy participants.
What is the current status of trial NCT05330858?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-03-17. Estimated completion is 2022-09-20.
What conditions does trial NCT05330858 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT05330858?
The interventions under investigation include: ESK-001 (DRUG), Rabeprazole (DRUG).
Who is sponsoring clinical trial NCT05330858?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05330858 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
-
Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination
RECRUITING · Phase 1
-
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.